Companies
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Orchard To Use Divested GSK Rare Disease Gene Therapies To Grow Globally
Orchard Therapeutics will acquire GSK’s portfolio of approved and investigational rare disease gene therapies, including EU-approved Strimvelis and additional late-stage gene therapies.
Companies
Latest From Companies
Modus CEO Says Rare Disease Priority Review Voucher To Be Key Catalyst
The US FDA gives Sweden's privately held Modus Therapeutics rare pediatric disease designation for sickle cell disease.
IOnctura CEO On Pipeline Strategy And Funding Goals
IOnctura’s CEO Catherine Pickering outlines the company’s business model and its approach to cancer R&D targeting the tumor microenvironment.
How Will Novel Agents Impact The HIV Market?
ViiV and Merck are looking to novel mechanisms of action as an opportunity to make up ground on HIV leader Gilead, which has de-emphasized early virology research.
Pipeline Growth Dropped Sharply in 2017 But Size Tops 15K
The number of products in active development by the pharma and biotech industries has topped 15,000 for the first time but the rate of the pipeline growth has slowed to just 2.7%, the lowest for five years, shows a new analysis by Citeline.
Servier Acquires Shire Oncology Business For $2.4bn
French pharma Servier takes step to meet its strategic ambition of becoming a global player in oncology by acquiring Shire's cancer franchise for $2.4bn
AXL Inhibition Specialist BerGenBio's $24m Private Placement To Fund Pipeline, Trials
BerGenBio CEO says the Norwegian biotech aims, either alone or in partnership, to develop and commercialize its lead asset through to marketing approval in a variety of cancers.
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.